GSK To Invest $250 Million In Vir For Potential Possible Covid-19 Treatments
An investment of $250 million in Vir Biotechnology Inc., along with collaboration, will be made by British drugmaker GlaxoSmithKline for the development of possible treatment for Covid-19, the disease caused by the novel coronavirus. Following this announcement by the companies, there was a 35 per cent jump in the shares of Vir while a 1…









